May 28, 2017 1:01 AM ET

Pharmaceuticals

Company Overview of Alcobra Ltd.

Company Overview

Alcobra Ltd., a biopharmaceutical company, focuses on the development and commercialization of proprietary pharmaceutical products. The company’ s product candidates include Abuse-Deterrent Amphetamine Immediate-Release (ADAIR), a proprietary, abuse-deterrent oral formulation of immediate-release (short-acting) dextroamphetamine for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy; and Metadoxine Extended Release (MDX), a proprietary oral drug for the treatment of ADHD and other cognitive disorders, including Fragile X syndrome. Alcobra Ltd. was founded in 2008 and is headquartered in Tel Aviv, Israel.

Azrieli Triangle Building

39th Floor

132 Derech Menachem Begin

Tel Aviv,  6701101

Israel

Founded in 2008

19 Employees

Phone:

972 72 220 4661

Key Executives for Alcobra Ltd.

Chief Executive Officer, President and Director
Age: 41
Total Annual Compensation: $469.0K
Chief Financial Officer and Chief Operating Officer
Age: 36
Total Annual Compensation: $393.0K
Chief Commercial Officer
Age: 53
Total Annual Compensation: $405.0K
Chief Medical Officer
Age: 55
Total Annual Compensation: $383.0K
Senior Vice President of Chemistry Manufacturing & Controls
Age: 65
Total Annual Compensation: $138.0K
Compensation as of Fiscal Year 2016.

Alcobra Ltd. Key Developments

Alcobra Ltd. expected to report Q1 2017 results on May 19, 2017. This event was calculated by Capital IQ (Created on May 13, 2017).

Alcobra Ltd. expected to report Q1 2017 results on May 19, 2017. This event was calculated by Capital IQ (Created on May 13, 2017).

Alcobra Ltd. - Analyst/Investor Day

Alcobra Ltd. - Analyst/Investor Day

Brower Piven Announces a Class Action Lawsuit in the United States District Court for the Southern District of New York on Behalf of Purchasers of Alcobra, Ltd. Securities

Brower Piven announced that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Alcobra Ltd. securities during the period between August 13, 2015 and January 17, 2017, inclusive. Investors who wish to become proactively involved in the litigation have until April 18, 2017 to seek appointment as lead plaintiff. The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants' failure to disclose during the Class Period that the company's statements regarding the measure study discounted the results of the October 2014 Phase III Study, assumed that if extreme placebo response patients were removed from the analysis, a statistically significant trend in favor of metadoxine extended release would result, which did not, and were based upon disregarding Attention Deficit Hyperactivity Disorder patients who improved with a placebo.

Similar Private Companies By Industry

Company Name Region
Abital Pharma Pipelines Ltd. Middle East/Africa
Active PX Ltd. Middle East/Africa
Advanced Inhalation Technology Ltd. Middle East/Africa
AIT Therapeutics, Inc. Middle East/Africa
Angio B Ltd. Middle East/Africa

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Alcobra Ltd., please visit www.alcobra-pharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.